Unicycive Therapeutics, Inc. Files Form 8-K: Key Details for Investors

Overview

Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage pharmaceutical company based in Los Altos, California, has filed a Form 8-K with the U.S. Securities and Exchange Commission dated April 6, 2026. The filing relates to Item 5.02, which covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.

Key Highlights from the Filing

• Form Type: 8-K (Current Report)
• Filing Date: April 6, 2026
• Company Name: Unicycive Therapeutics, Inc.
• Trading Symbol: UNCY
• Exchange: Nasdaq Capital Market
• Business Address: 4300 El Camino Real, Suite 210, Los Altos, CA 94022
• Phone: (650) 351-4495
• Industry: Pharmaceutical Preparations (SIC 2834)
• Emerging Growth Company: Yes (the company checked the box indicating it qualifies as an emerging growth company)
• Extended Transition Period for Financial Accounting Standards: The company has not elected to use the extended transition period.

Potentially Price-Sensitive Information

The Form 8-K filing indicates that there have been changes or actions relating to directors or certain officers of the company, including possible departures, elections, appointments, or changes to their compensatory arrangements. Such developments are often material and can move the share price, as they may reflect strategic changes, management transitions, or shifts in corporate governance.

However, it is important to note: The specific details of any director or officer departure, new appointments, or compensation changes are not present in the provided filing content. There are no named individuals or specific actions disclosed in the text available. The filing appears to be a cover and summary page, and does not include the narrative or tabular disclosure normally associated with Item 5.02 events.

What Shareholders Should Know

• Corporate Governance Event: The company has triggered Item 5.02 of Form 8-K, which is reserved for significant changes in the executive team or board of directors, or material changes to officer compensation. These events are closely watched by the market given their potential impact on company direction and performance.
• No Details Disclosed: As of this filing, there are no specific names, actions, or details provided in the document regarding which directors or officers are affected, or the nature of any new appointments or compensation arrangements.
• Stock Information: Unicycive’s common stock continues to trade under the ticker UNCY on the Nasdaq Capital Market. No changes to the trading status, symbol, or exchange have been reported.
• Regulatory Compliance: The company is in compliance with the current reporting requirements and is classified as an emerging growth company, which may provide it with certain regulatory and financial reporting accommodations.

Conclusion

While the filing of a Form 8-K under Item 5.02 is usually material and can affect the share price, the lack of specific disclosures in the body of the filing means that investors do not have actionable information at this time. Investors are advised to remain alert for any subsequent filings, press releases, or public statements from Unicycive Therapeutics, Inc. that may provide further details regarding the corporate governance event referenced.

There is currently no disclosed information in this filing that would directly move the share price; however, the potential for news regarding management or board changes warrants ongoing attention.

Disclaimer: This article is a summary and interpretation of regulatory filings made by Unicycive Therapeutics, Inc. to the SEC. It does not constitute investment advice. Investors should consult the company’s official releases and filings with the SEC for complete and up-to-date information before making any investment decisions.

View Unicycive Therapeutics, Inc. Historical chart here